Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma

Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma

Choroid plexus carcinomas (CPCs) are rare, aggressive pediatric brain tumors with no established curative therapy for relapsed disease, and poor survival rates. TP53 Mutation or dysfunction correlates with poor or no survival outcome in CPCs. Here, we report the case of a 4 month-old female who pres...

Full description

Bibliographic Details
Main Authors: Albert Cornelius, Jessica Foley, Jeffrey Bond, Abhinav B. Nagulapally, Julie Steinbrecher, William P. D. Hendricks, Maria Rich, Sangeeta Yendrembam, Genevieve Bergendahl, Jeffrey M. Trent, Giselle S. Sholler
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-09-01
Series:Frontiers in Pharmacology
Subjects:
choroid plexus carcinoma
molecular guided therapy
mTOR
TP53
IDH2
Online Access:http://journal.frontiersin.org/article/10.3389/fphar.2017.00652/full

Internet

http://journal.frontiersin.org/article/10.3389/fphar.2017.00652/full

Similar Items